Cargando…

Astragalus propinquus schischkin and Salvia miltiorrhiza bunge promote angiogenesis to treat myocardial ischemia via Ang-1/Tie-2/FAK pathway

Astragalus propinquus Schischkin and Salvia miltiorrhiza Bunge (AS) have been clinically used as adjunctive drugs in the treatment of myocardial ischemia (MI). However, the effect and mechanism of AS on MI have yet to be fully recognized. Here, we explored the cardioprotective effect of their combin...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Mu-Xin, Huang, Xue-Ying, Song, Yu, Xu, Wan-Li, Li, Yun-Lun, Li, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868545/
https://www.ncbi.nlm.nih.gov/pubmed/36699092
http://dx.doi.org/10.3389/fphar.2022.1103557
_version_ 1784876561794596864
author Zhang, Mu-Xin
Huang, Xue-Ying
Song, Yu
Xu, Wan-Li
Li, Yun-Lun
Li, Chao
author_facet Zhang, Mu-Xin
Huang, Xue-Ying
Song, Yu
Xu, Wan-Li
Li, Yun-Lun
Li, Chao
author_sort Zhang, Mu-Xin
collection PubMed
description Astragalus propinquus Schischkin and Salvia miltiorrhiza Bunge (AS) have been clinically used as adjunctive drugs in the treatment of myocardial ischemia (MI). However, the effect and mechanism of AS on MI have yet to be fully recognized. Here, we explored the cardioprotective effect of their combined use, and the mechanism of promoting angiogenesis through pericyte recruitment. Our data revealed that AS reduced MI and protects cardiac function. AS-treated MI mice exhibited reduced ST-segment displacement and repolarization time, increased ejection fraction, and less BNP and NT-proBNP expression. Pathological studies showed that, AS reduced the area of infarcted myocardium and slowed down the progress of cardiac remodelling and fibrosis. In addition, AS increased the content of platelet-derived growth factor receptors β (PDGFR-β), platelet endothelial cell adhesion molecule-1 (CD31) and angiogenesis-related proteins including vascular endothelial cadherin (VE-cadherin), Vascular Endothelial Growth Factor (VEGF) and transforming growth factor β (TGF-β). Moreover, these botanical drugs upregulated the expression of Angiopoietin-1 (Ang-1), phosphorylated angiopoietin-1 receptor (p-Tie-2), focal adhesion kinase (FAK) and growth factor receptor bound protein 7 (GRB7), indicating that the cardioprotection-related angiogenesis effect was related to pericyte recruitment, which may be through Ang-1/Tie-2/FAK pathway. In summary, AS can treat MI by protecting cardiac function, attenuating cardiac pathological changes, and hindering the progression of heart failure, which is related to angiogenesis after pericyte recruitment. Therefore, AS at a certain dose can be a promising treatment for MI with broad application prospects.
format Online
Article
Text
id pubmed-9868545
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98685452023-01-24 Astragalus propinquus schischkin and Salvia miltiorrhiza bunge promote angiogenesis to treat myocardial ischemia via Ang-1/Tie-2/FAK pathway Zhang, Mu-Xin Huang, Xue-Ying Song, Yu Xu, Wan-Li Li, Yun-Lun Li, Chao Front Pharmacol Pharmacology Astragalus propinquus Schischkin and Salvia miltiorrhiza Bunge (AS) have been clinically used as adjunctive drugs in the treatment of myocardial ischemia (MI). However, the effect and mechanism of AS on MI have yet to be fully recognized. Here, we explored the cardioprotective effect of their combined use, and the mechanism of promoting angiogenesis through pericyte recruitment. Our data revealed that AS reduced MI and protects cardiac function. AS-treated MI mice exhibited reduced ST-segment displacement and repolarization time, increased ejection fraction, and less BNP and NT-proBNP expression. Pathological studies showed that, AS reduced the area of infarcted myocardium and slowed down the progress of cardiac remodelling and fibrosis. In addition, AS increased the content of platelet-derived growth factor receptors β (PDGFR-β), platelet endothelial cell adhesion molecule-1 (CD31) and angiogenesis-related proteins including vascular endothelial cadherin (VE-cadherin), Vascular Endothelial Growth Factor (VEGF) and transforming growth factor β (TGF-β). Moreover, these botanical drugs upregulated the expression of Angiopoietin-1 (Ang-1), phosphorylated angiopoietin-1 receptor (p-Tie-2), focal adhesion kinase (FAK) and growth factor receptor bound protein 7 (GRB7), indicating that the cardioprotection-related angiogenesis effect was related to pericyte recruitment, which may be through Ang-1/Tie-2/FAK pathway. In summary, AS can treat MI by protecting cardiac function, attenuating cardiac pathological changes, and hindering the progression of heart failure, which is related to angiogenesis after pericyte recruitment. Therefore, AS at a certain dose can be a promising treatment for MI with broad application prospects. Frontiers Media S.A. 2023-01-09 /pmc/articles/PMC9868545/ /pubmed/36699092 http://dx.doi.org/10.3389/fphar.2022.1103557 Text en Copyright © 2023 Zhang, Huang, Song, Xu, Li and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zhang, Mu-Xin
Huang, Xue-Ying
Song, Yu
Xu, Wan-Li
Li, Yun-Lun
Li, Chao
Astragalus propinquus schischkin and Salvia miltiorrhiza bunge promote angiogenesis to treat myocardial ischemia via Ang-1/Tie-2/FAK pathway
title Astragalus propinquus schischkin and Salvia miltiorrhiza bunge promote angiogenesis to treat myocardial ischemia via Ang-1/Tie-2/FAK pathway
title_full Astragalus propinquus schischkin and Salvia miltiorrhiza bunge promote angiogenesis to treat myocardial ischemia via Ang-1/Tie-2/FAK pathway
title_fullStr Astragalus propinquus schischkin and Salvia miltiorrhiza bunge promote angiogenesis to treat myocardial ischemia via Ang-1/Tie-2/FAK pathway
title_full_unstemmed Astragalus propinquus schischkin and Salvia miltiorrhiza bunge promote angiogenesis to treat myocardial ischemia via Ang-1/Tie-2/FAK pathway
title_short Astragalus propinquus schischkin and Salvia miltiorrhiza bunge promote angiogenesis to treat myocardial ischemia via Ang-1/Tie-2/FAK pathway
title_sort astragalus propinquus schischkin and salvia miltiorrhiza bunge promote angiogenesis to treat myocardial ischemia via ang-1/tie-2/fak pathway
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868545/
https://www.ncbi.nlm.nih.gov/pubmed/36699092
http://dx.doi.org/10.3389/fphar.2022.1103557
work_keys_str_mv AT zhangmuxin astragaluspropinquusschischkinandsalviamiltiorrhizabungepromoteangiogenesistotreatmyocardialischemiaviaang1tie2fakpathway
AT huangxueying astragaluspropinquusschischkinandsalviamiltiorrhizabungepromoteangiogenesistotreatmyocardialischemiaviaang1tie2fakpathway
AT songyu astragaluspropinquusschischkinandsalviamiltiorrhizabungepromoteangiogenesistotreatmyocardialischemiaviaang1tie2fakpathway
AT xuwanli astragaluspropinquusschischkinandsalviamiltiorrhizabungepromoteangiogenesistotreatmyocardialischemiaviaang1tie2fakpathway
AT liyunlun astragaluspropinquusschischkinandsalviamiltiorrhizabungepromoteangiogenesistotreatmyocardialischemiaviaang1tie2fakpathway
AT lichao astragaluspropinquusschischkinandsalviamiltiorrhizabungepromoteangiogenesistotreatmyocardialischemiaviaang1tie2fakpathway